Please use this identifier to cite or link to this item:
|Title:||Oral trivalent bismuth ions decrease, and trivalent indium or ruthenium ions increase, intestinal tumor burden in ApcΔ14/+ mice.||Austin Authors:||Laval, Marie;Dumesny, Chelsea;Eutick, Mal;Baldwin, Graham S;Marshall, Kathryn M||Affiliation:||University of Melbourne Department of Surgery, Austin Health, Heidelberg, Victoria, Australia
Phebra Pty. Ltd., Lane Cove West, New South Wales, Australia
|Issue Date:||24-Jan-2018||Publication information:||Metallomics : integrated biometal science 2018; 10(1): 194-200||Abstract:||Immature forms of the peptide hormone gastrin have been implicated in the development of colorectal cancer (CRC). The biological activity of glycine-extended gastrin (Ggly) is dependent on the binding of Fe3+ ions in vitro and in vivo. The aim of the present study was to determine the effect of blocking Fe3+ ion binding to Ggly, using Bi3+, In3+ or Ru3+ ions, on the development of intestinal tumors in APCΔ14/+ mice. APCΔ14/+ mice were treated orally with Bi3+, In3+ or Ru3+ ions for up to 60 days, serum trace metals were analyzed by inductively coupled plasma mass spectrometry, and the incidence and size of intestinal tumors were assessed. Bi3+ treatment significantly decreased the number of tumors larger than 3 mm in male mice. In3+ or Ru3+ treatment significantly increased the tumor burden in all animals and In3+ increased the number of tumors larger than 3 mm or 5 mm in male mice alone. The fact that binding of In3+ or Ru3+ ions to Ggly was orders of magnitude stronger than the binding of Bi3+ ions implies that the inhibitory effect of Bi3+ ions is not a consequence of a reduction in Ggly activity. However, further testing of higher doses of Bi3+ ions for longer periods as an oral treatment for intestinal tumors is warranted.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/17150||DOI:||10.1039/c7mt00272f||Journal:||Metallomics : integrated biometal science||PubMed URL:||29296993||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 7, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.